Zobrazeno 1 - 10
of 412
pro vyhledávání: '"Toyoaki Hida"'
Autor:
Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100685- (2024)
Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in ALK-positive or ALK-negative advanced NSCLC, respectively. Methods: Starting d
Externí odkaz:
https://doaj.org/article/50d39c846b474baea88547c6b345e6aa
Autor:
Hye Ryun Kim, Shunichi Sugawara, Jong‐Seok Lee, Jin‐Hyoung Kang, Naoki Inui, Toyoaki Hida, Ki Hyeong Lee, Tatsuya Yoshida, Hiroshi Tanaka, Cheng‐Ta Yang, Makoto Nishio, Yuichiro Ohe, Tomohide Tamura, Nobuyuki Yamamoto, Chong‐Jen Yu, Hiroaki Akamatsu, Shigeru Takahashi, Kazuhiko Nakagawa
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 17061-17067 (2023)
Abstract Background ONO‐4538‐52/TASUKI‐52 was performed in Japan, Korea, and Taiwan to determine the oncological effectiveness and safety of combining nivolumab or placebo with bevacizumab plus platinum chemotherapy for the initial (first‐lin
Externí odkaz:
https://doaj.org/article/b0fcd685eeec41798eee2fd83380a4ba
Autor:
Yuki Katsuya, Shigehisa Kitano, Makiko Yamashita, Mayu Ouchi, Shigehiro Yagishita, Akinobu Hamada, Hiromi Nakamura, Fumie Hosoda, Tatsuhiro Shibata, Noriko Motoi, Takayuki Nakayama, Takashi Seto, Shigeki Umemura, Yukio Hosomi, Miyako Satouchi, Makoto Nishio, Toshiyuki Kozuki, Toyoaki Hida, Yuichiro Ohe, Hidehito Horinouchi
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
In a phase II trial of nivolumab in advanced thymic carcinoma (UMIN000022007), long SD (SD for more than 24 weeks) was seen in three patients and irAE (Gr2 or higher) was seen in four patients among 15 patients. Here, we report preplanned comprehensi
Externí odkaz:
https://doaj.org/article/2545d4e201224695ad24cf1e5f197dd5
Autor:
Teppei Yamaguchi, Junichi Shimizu, Takaaki Hasegawa, Yoshitsugu Horio, Yoshitaka Inaba, Nobuhiro Hanai, Kei Muro, Toyoaki Hida
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, has shown survival benefit in clinical trials of various malignant tumors. Nivolumab-induced pneumonitis is major immune-related adverse event (irAE) that is occasi
Externí odkaz:
https://doaj.org/article/49bab5461f5f4811961b5dd4829adb02
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 2, Pp 886-891 (2021)
Fenbendazole is a benzimidazole anthelmintic agent, with a broad antiparasitic range in animals such as dogs and pigs. The agent is also reported to exert antitumor effects and inhibit microtubule-associated tubulin polymerization, but its safety and
Externí odkaz:
https://doaj.org/article/35082cf3258d48249057ff134cfc5710
Autor:
Yuko Oya, Tatsuya Yoshida, Kazuhiro Asada, Tetsuya Oguri, Naoki Inui, Sayako Morikawa, Kentaro Ito, Tomoki Kimura, Eiji Kunii, Takashi Matsui, Akihito Kubo, Tatsuo Kato, Takashi Abe, Takeshi Tsuda, Toyoaki Hida
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Cell-free DNA (cfDNA) genotyping in plasma using the cobas EGFR Mutation Test v2 (cobas) is the first liquid biopsy as a companion diagnosis to identify the EGFR T790M mutation (T790M) after the failure of treatment of EGFR-tyrosi
Externí odkaz:
https://doaj.org/article/d915076e6bac4eb1895be47a387165cd
Autor:
Katsutoshi Seto, Katsuhiro Masago, Shiro Fujita, Masataka Haneda, Yoshitsugu Horio, Toyoaki Hida, Hiroaki Kuroda, Waki Hosoda, Ken‐ichi Okubo
Publikováno v:
Thoracic Cancer, Vol 11, Iss 7, Pp 1827-1834 (2020)
Abstract Background RNA‐based sequencing is considered ideal for detecting pathogenic fusion‐genes compared to DNA‐based assays and provides valuable information about the relative expression of driver genes. However, RNA from formalin‐fixed
Externí odkaz:
https://doaj.org/article/40930be6af934023b8a71cbed7818f3c
Autor:
Nahomi Tokudome, Yasuhiro Koh, Hiroaki Akamatsu, Daichi Fujimoto, Isamu Okamoto, Kazuhiko Nakagawa, Toyoaki Hida, Fumio Imamura, Satoshi Morita, Nobuyuki Yamamoto
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Epidermal growth factor receptor (EGFR)-sensitizing mutation, exon 19 deletion consists of several molecular variants. Influences of these variants on clinical response to EGFR tyrosine kinase inhibitors remain elusive. Methods We
Externí odkaz:
https://doaj.org/article/b60fdaae47f44203886f8b43ab41f084
Autor:
Hidehito Horinouchi, Makoto Nishio, Toyoaki Hida, Kazuhiko Nakagawa, Hiroshi Sakai, Naoyuki Nogami, Shinji Atagi, Toshiaki Takahashi, Hideo Saka, Mitsuhiro Takenoyama, Nobuyuki Katakami, Hiroshi Tanaka, Koji Takeda, Miyako Satouchi, Hiroshi Isobe, Makoto Maemondo, Koichi Goto, Tomonori Hirashima, Koichi Minato, Naoki Sumiyoshi, Tomohide Tamura
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 5183-5193 (2019)
Abstract Background Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. It is associated with longer overall survival (OS) than the standard treatment of docetaxel in patients wi
Externí odkaz:
https://doaj.org/article/98ef3513e3d64aad8fdc1d5b550e05c4
Autor:
Takehiro Uemura, Kensuke Fukumitsu, Ken Maeno, Satoshi Fukuda, Tomohiro Onuki, Yoshihiro Kanemitsu, Tetsuya Oguri, Akio Niimi, Toyoaki Hida
Publikováno v:
Respirology Case Reports, Vol 9, Iss 9, Pp n/a-n/a (2021)
Abstract Durvalumab, an anti‐programmed cell death‐ligand 1 (PD‐L1) antibody, is currently used in the maintenance therapy for patients with stage III non‐small cell lung cancer after platinum‐based chemoradiotherapy. A 69‐year‐old male
Externí odkaz:
https://doaj.org/article/a3ee84ccf45a46c7be7e349a1e289886